

blood-borne infection (3). Information in this regard may be helpful to countries where HCV-related HCC is endemic, such as Mongolia, Myanmar and Taiwan.

Another example is lung cancer. Many Asian countries have high smoking rates in males. Male smoking rates in Japan have been decreasing, and the incidence of lung cancer has been decreasing since 1993, and also reduced incidence of squamous cell carcinoma because of a change from non-filter to filter cigarettes. The incidence rate of squamous cell carcinoma has been decreasing since 1994, whereas the incidence rate of adenocarcinoma increased until 1998, after which it plateaued. It took nearly 30 years for the decrease in non-filtered cigarettes to translate into a decrease in squamous cell carcinoma. Although it takes a long time, anti-smoking policies reduce the incidence of lung cancer. Evidence of this has been presented in Western countries, and it is important to advance such policies in Asia, as well, in order to reduce lung cancer.

A study group financially supported by a Grant-in-Aid for Comprehensive Cancer Control from Japanese Ministry of Health, Labor and Welfare conducted a collaborative study using a population-based cancer registry in East Asia (4). They have reported a 5-year relative survival rate of stomach cancer patients diagnosed between 1997 and 1999. The survival rates were higher in Japan, and even in Korea and Taiwan, than in Europe and the USA. The breast cancer 5-year survival rate was very high in Japan, Korea and Taiwan, and almost the same as in the EU and USA, whereas the survival rate of breast cancer was low in the Philippines, and hence improvement is needed there. The highest cervical cancer 5-year survival rate was seen in Korea, whereas several regions in Japan were not so high. Elucidation of the reasons for the lower rates in Japan is needed. Again, the Philippines had the lowest 5-year survival rate for cervical cancer, as well.

The next stage for cooperative studies is to collect individualized, anonymous data, which would make it possible to elucidate the factors that cause differences between populations, such as age, clinical stage at diagnosis, treatment procedures, etc. Individualized, anonymous data would also improve the comparability of survival data among the participating regions.

In conclusion, designing cooperative studies using cancer registry data involves a first stage in which information is exchanged among the participating countries to facilitate cancer control planning, a second stage consisting of a comparative study using non-individualized data and a third stage using individualized data (Fig. 2). Good human relationships among researchers are also very important, and the APCC represents a good platform for nurturing such good relationships.

COLLABORATIVE EPIDEMIOLOGICAL STUDIES FOR CANCER PREVENTION

With regard to collaborative epidemiological studies to collect evidence concerning cancer risk and protective




Figure 2. Designing a cooperative study using cancer registry data.

factors in the Asian region, recent trends show that the number of studies has been increasing, meta-analysis/pooled analysis of multiple studies has become very popular, and the importance of estimating the population-attributable fraction in each country/region/world has been recognized.

Collaboration between two countries is fairly simple, consisting of securing a research grant/funding, data collection by investigators and co-investigators in each country, and data analysis and manuscript preparation. The data center, data analysis and manuscript preparation are usually in the country of the principal investigator, while the grant is usually executed in the currency of the funding host.

In the case of collaboration between multiple countries, things get more complicated. The principal investigator is in one country, with a network including co-investigators collecting data in each of the participating countries, and the data analysis and manuscript preparation are performed at a data center, usually in the country of the principal investigator. However, the location of the data center and the manuscript writer are flexible.

An even more complicated example of collaboration is the Asia Cohort Consortium, which includes investigators from various countries and who change in accordance with the topic (Fig. 3). Interesting features are that the data center is outside Asia, in the USA, and the researchers include not only Asians but also Europeans and Americans, because they get funding, by topic, from their countries. Also, there is no firm funding base for network maintenance.

The funding agency in support of epidemiological research can be a domestic organization or an international organization. In the case of a domestic organization, the study is based in that country and is usually research topic-oriented. In the case of an international organization, the study base can be anywhere, and it is a potential research platform.

For good epidemiological research collaboration in Asian countries, the following points are important: each researcher must have an understanding of the significance of




Figure 3. Collaboration between multiple countries: Example: Asia Cohort Consortium.

multinational collaborative studies; the leader must be a good coordinator; funding must be available for network maintenance and a multinational consortium; and the collaboration must be balanced and provide equal opportunity.

CONCLUSIONS

The problems that are faced in relation to cancer registry in Asia are various (Fig. 4). They include insufficient quality of most registries, weak infrastructure, inadequate coverage in some countries, difficulty in sustainability due to insufficient financial support and turnover of trained personnel, few opportunities for education and training, and low response rates to IACR questionnaire surveys. Similarly, problems in relation to epidemiological studies include wide variation in expertise and resources among Asian countries, and limited understanding of epidemiology in some nations, which constrains funding for epidemiological studies (Fig. 5). Other key problems are the lack of opportunity for contact between experts in Asia via collaborative activities and language barriers among Asian countries.

As solutions, from the perspective of researchers, the highest priority should be placed on information-sharing among researchers within the Asia-Pacific region. Newly developed and widely used techniques, such as those for record linkage, should be shared. In addition, there is a need to promote coordination meetings/workshops/symposia, provide training courses, establish international standards and promote collaborative studies, publication and a common database for pooled analysis, both for cancer registries and epidemiological studies. In order to do this, an organization for Asian cooperation on cancer registration should be established in the field of cancer registries. In addition, a common hub for collaborative research will be needed for epidemiological studies. More opportunities for collaborative research projects, activities and publications

Problems

Cancer Registry

- Insufficient quality in most cancer registries
 - Quality Index, such as DCO%, MI ratio or MV% are low in Asian countries compared to North America and Europe
- Weak infrastructure
 - Nation wide mortality statistics are not available in some countries
 - Legislative basis is weak in some countries
 - Human and financial resources are insufficient
- Insufficient coverage
 - Some countries have no population based cancer registry at all.
- Difficulties in sustainability
 - Due to insufficient financial support, rapid turn over of trained personnel
- Few occasions of education and training
- Low response rates for the questionnaire surveys from IACR
 - The contact list of the registries is not maintained officially and adequately

Figure 4. Problems: Cancer Registry.

Problems

Epidemiological Study

- Wide variation in the expertise and resources of epidemiological research by country within Asia.
 - Within Asia, there exists wide variation in the availability of resources and expertise between countries, generally more available in Eastern Asia including Japan, Korea and China than the rest of Asia.
- Epidemiologic evidences from Asian population insufficient compared with Western regions
 - Although the number of epidemiological study has increased in Asia, it is still smaller than in Western region and insufficient to formulate public health policy specific to each country/Asian population.
- Limited understanding of epidemiological study
- Limited funding for epidemiological study

Figure 5. Problems: Epidemiological Study.

would improve the research skills and expertise in the region.

From the perspective of international organizations, such as the IARC and IACR, in a 2009 meeting the governing council of the IARC discussed how to provide greater support to cancer registries in developing countries. The IARC/IACR is planning to create a password-protected online system, so that questionnaires can be completed online and updated every year. The website would also allow registries to update their contact information. In October 2010, an Asian session will be held as a post-conference of the IACR annual meeting in Yokohama, Japan and Asian cooperation in cancer registration will be one of the main themes. To maintain a network of cancer registries, or an Asia Cohort Consortium, it will be necessary to maintain funding not only for topic-specific research proposals, but also for the research platform itself. To that end, funding should also be requested of other organizations.

In the future, the Asia-Pacific region must make full use of the platforms afforded by the WHO, IARC/IACR, UICC Headquarters, APFOCC and liaison societies in order to promote and achieve its goals of establishing cancer registries, accumulating cancer statistics, promoting and performing epidemiological studies and formulating regional and national cancer control programs.

With regard to concrete actions, from the perspective of researchers, there must be continued development of collaborative research projects and activities in subregions such as West Asia, Central Asia, Southeast Asia, East Asia and the Pacific. Publication of these activities should be encouraged to improve research skills and expertise in the study of Asia-Pacific populations. In that context, a steering committee for Asian cooperation for cancer registration will be assembled for the kick-off meeting in Yokohama 2010. At the same time, it will be proposed that the IARC supports the administrative work needed to maintain the network. Finally, collaborative and comparative epidemiological studies based on data from cancer registries should be promoted.

Funding

This working group meeting was financially supported by The Health and Labor Sciences Research Grant for Third Term Comprehensive Control Research for Cancer from Ministry of Health, Labor and Welfare, Japan, Grant-in-Aid for Cancer Research on Priority Areas from the Ministry of Education, Science, Sports Culture and Technology, Japan, 20th Asia Pacific Cancer Conference (President: Dr Hideyuki Akaza) and International Union Against Cancer (UICC) Asia Regional Office.

Conflict of interest statement

None declared.

Appendix

Abdulbari Bener, Epidemiology and Medical Statistics, Weil Cornell Medical College in Qatar, Hamad Medical Corporation, Qatar; Adriano V. Laudico, Department of Surgery, University of the Philippines Manila, Philippine General Hospital, Philippines; Aleyamma Mathew, Cancer Registry and Epidemiology, Regional Cancer Centre, India; Alireza Mosavi-Jarrahi, Department of Social Medicine, Medical School Shahid, Beheshti University of Medical Sciences, Iran; Cahyono Kaelan, Department of Pathology, Hasanuddin University, Indonesia; Chisato Nagata, Department of Epidemiology and Prevention Medicine, Gifu University Graduate School of Medicine, Japan; Chun-Xiao Wu, Department of Cancer Control and Prevention, Shanghai Municipal Center for Disease Control and

Prevention, China; Daehee Kang, Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University College of Medicine, Korea; David Roder, Cancer Council South Australia, Australia; Dong-Hyun Kim, Department of Social and Preventive Medicine, Hallym University College of Medicine, Korea; Ediati Triningsih, Department of Pathology, Gadjadara University Faculty of Medicine, Indonesia; Evlina Suzanna Sinuraya, Department of Pathology, Dharmas National Cancer Center, Indonesia; Francine Baumann, Cancer Registry of New Caledonia, New Caledonia; Hai-Rim Shin, Western Pacific Regional Office, World Health Organization, Philippines; Hideaki Tsukuma, Cancer Control & Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan; Javad Shokrishirvani, Department of Gastroenterology, Babol University of Medical Sciences, Iran; Jun Miyake, Department of Mechanical Science and Bioengineering, Graduate School of Engineering Science, Osaka University, Japan; Kazuo Tajima, Aichi Cancer Center Hospital and Research Institute, Japan; Keitaro Matsuo, Division of Epidemiology and Prevention, Aichi Cancer Center Hospital and Research Institute, Japan; Keun-Young Yoo, Department of Preventive Medicine, Seoul National University College of Medicine, Korea; Malcolm Moore, UICC Asian Regional Office, Asian Pacific Journal of Cancer Prevention / Asian Pacific Organization for Cancer Prevention, Japan; Marc Goodman, Cancer Research Center, University of Hawaii, U.S.; Maria Rica Mirasol Lumague, Department of Health - Rizal Cancer Registry, Rizal Medical Center, Philippines; Mashhura Soipova, Uzbek Ministry of Health, Uzbekistan; Mei-Shu Lai, Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taiwan; Mohammad Ali Mohagheghi, Department Surgery, The Cancer Institute, Imam Khomeini Medical Complex, Iran; Ngoan Tran Le, Occupational Health, Hanoi Medical University, Viet Nam; Noorwati Sutandyo, Dharmas Cancer Hospital, Indonesia; Nor Hayati Othman, Pathology, Universiti Sains Malaysia, Malaysia; Norie Kawahara, Research Center for Advanced Science & Technology, The University of Tokyo, Japan; Nurbek S. Iginov, Department of Scientific Programs Management, Astana Medical University, Kazakhstan; Reza Ghadimi, Department of Social Medicine and Health, Babol University of Medical Sciences, Iran; Shinkan Tokudome, National Institute of Health and Nutrition, Japan; Shiro Hinotsu, Department of Pharmacoepidemiology, Kyoto University; Sohee Park, Cancer Registration and Biostatistics Branch, National Cancer Center Research Institute, Korea; Sultan Eser, Izmir Cancer Registry, Turkey; Suminori Kono, Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Japan; Sunia Foliaki, Centre for Public Health Research, Massey University, New Zealand; Supanee Promthet, Department of Epidemiology, Faculty of Public Health, Khon Kaen University, Thailand; Surapon Wiangnon, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Thailand; Tetsuya Mizoue,

Department of Epidemiology and International Health, Research Institution International Medical Center of Japan; Tohru Masui, National Institute of Biomedical Innovation, Japan; Wanqing Chen, Chun-Xiao Wu, National Office for Cancer Prevention and Control, China; Yasmin Bhurgri, Karachi Cancer Registry, Pakistan; Yoon-OK Ahn, Department of Preventive Medicine, Seoul National University College of Medicine, Korea; You-Lin Qiao, Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, China.

References

1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. editors. *Cancer Incidence in Five Continents*, Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC 2008.
2. Ferlay J, Bray F, Piani P, Parkin DM. *GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2.0*. Lyon: IARC Press 2004.
3. Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. *Ann Intern Med* 2008;148:820–6.
4. Tanaka H, Tanaka M, Chen W, Park S, Jung KW, Chiang CJ, et al. Proposal for a Cooperative Study on Population-based Cancer Survival in Selected Registries in East Asia. *Asian Pac J Cancer Prev* 2009;10(6):1191–8.

Epidemiology Note

Cancer Incidence and Incidence Rates in Japan in 2005: Based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project

Tomohiro Matsuda^{1,*}, Tomomi Marugame¹, Ken-ichi Kamo², Kota Katanoda¹, Wakiko Ajiki¹ and Tomotaka Sobue¹ The Japan Cancer Surveillance Research Group

¹Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo and ²Division of Mathematics, School of Medicine, Liberal Arts and Sciences, Sapporo Medical University, Sapporo, Hokkaido, Japan

*For reprints and all correspondence: Tomohiro Matsuda, Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: tomatsud@ncc.go.jp

Received July 20, 2010; accepted August 2, 2010

The Japan Cancer Surveillance Research Group estimated the cancer incidence in 2005 as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project, on the basis of data collected from 12 of 30 population-based cancer registries. The total number of incidences in Japan for 2005 was estimated as 646 802 (C00–C96). The leading cancer site was the stomach for men and the breast for women. Age-standardized incidence rates remained almost the same level as the previous 2 years.

Key words: cancer incidence – incidence estimates – cancer registry – Japan

The Japan Cancer Surveillance Research Group is involved in cancer monitoring in Japan since 2000 (1–5). This group estimated the cancer incidence in 2005 as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project, on the basis of data collected from 12 of 30 population-based cancer registries: Miyagi, Yamagata, Chiba, Kanagawa, Niigata, Fukui, Shiga, Tottori, Okayama, Hiroshima, Nagasaki and Kumamoto. If data from all 30 registries were used, this would have led to a large underestimation of national cancer incidence because of under-registration. The methods of registry selection, estimation of incidence and the limitations of these methods have been explained in previous studies (6–8). We maintained the same methodology since the MCIJ2003: (i) we invited all 30 population-based cancer registries in Japan to participate, and from these, we selected the 12 cancer registries with high-quality data in order to estimate the national incidence, and (ii) we used 2005 data alone for the national estimation. For this year, data from Osaka and Saga prefectures, regularly considered as one of the registries with high quality, were not available for the MCIJ project. The other registries remained since the previous estimation in 2004.

The number of incidences, crude rates, age-standardized rates and quality indicators of registration in 2005 are shown in Table 1, and the age-specific number of incidences and the rates according to sex and primary site are shown in Tables 2 and 3. The total number of incidences in Japan for 2005 was estimated as 646 802 (C00–C96). The time trends of age-standardized incidence rates for the five major sites and male- and female-specific sites in 1975–2005 are shown in Fig. 1 (standard population: the world population) and in Fig. 2 (standard population: the 1985 Japanese model population). The leading cancer site according to the crude and age-standardized incidence rates was the stomach for men and the breast for women since the research group took over national estimation of incidence, as shown in Figs 1 and 2. Age-standardized incidence rates remained almost the same level as the previous 2 years. It is thought to be partly due to that the development of hospital-based cancer registry in designated cancer care hospitals was calmed down in 2005. The estimated cancer incidence data in Japan by sex, site, 5-year age group and calendar year during the period 1975–2005 are available as a booklet and as an electronic database

Table 1. Incidence, completeness of reporting and accuracy of diagnosis in Japan according to sex and primary site, 2005

Primary sites	ICD-10th	Number of incidence	Crude rate ^a	Age-standardized rate ^a		Completeness of reporting		Accuracy of diagnosis
				World population	Japanese 1985 model population	DCO/I (%)	I/M	
Male								
All sites (incl. CIS)	C00–C96, D00–D09	390 835	626.9	288.5	408.4	14.9	1.99	74.8
All sites	C00–C96	379 436	608.6	279.7	396.1	15.2	1.93	74.3
Lip, oral cavity and pharynx	C00–C14	7417	11.9	6.0	8.2	12.8	1.79	80.6
Esophagus	C15	14 818	23.8	11.1	15.5	13.1	1.57	80.0
Stomach	C16	80 102	128.5	59.3	83.9	12.1	2.45	84.0
Colon	C18	37 126	59.5	27.1	38.7	10.3	2.76	84.1
Rectum	C19–C20	22 344	35.8	17.5	24.2	10.3	2.57	85.3
Colon and rectum	C18–C20	59 470	95.4	44.6	62.9	10.3	2.69	84.6
Liver	C22	28 729	46.1	21.4	30.1	23.5	1.24	31.3
Gallbladder etc.	C23–C24	9237	14.8	6.1	9.1	25.3	1.18	48.8
Pancreas	C25	13 108	21.0	9.5	13.5	26.5	1.07	35.9
Larynx	C32	3903	6.3	2.9	4.0	6.1	3.88	89.3
Trachea, bronchus and lung	C33–C34	58 264	93.4	39.4	58.5	21.7	1.29	68.8
Melanoma of skin etc.	C43–C44	4798	7.7	3.5	5.0	4.2	7.64	92.5
Prostate	C61	42 997	69.0	28.2	42.0	10.3	4.64	83.5
Bladder	C67	12 619	20.2	8.8	12.9	10.3	3.05	83.2
Kidney, renal pelvis, ureter etc.	C64–C66, C68	9758	15.7	7.7	10.6	13.2	2.43	76.1
Brain and nervous system	C70–C72	2496	4.0	2.8	3.3	25.3	2.71	68.2
Thyroid	C73	2126	3.4	2.0	2.6	4.5	4.77	91.0
Malignant lymphoma	C81–C85, C96	9667	15.5	8.0	10.9	12.4	1.99	86.1
Multiple myeloma	C88, C90	2242	3.6	1.5	2.3	23.2	1.14	67.4
All leukaemias	C91–C95	5200	8.3	5.3	6.3	21.6	1.21	85.9

Table 2. Age-specific incidence in Japan according to sex and primary site, 2005

Primary sites	ICD-10th	Age group (years)																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
Male																			
All sites (incl. CIS)	C00-C96, D00-D09	411	251	264	325	694	915	1592	2633	4640	7543	17 618	34 039	47 157	60 310	73 404	69 067	40 247	29 725
All sites	C00-C96	411	247	264	320	694	895	1577	2540	4422	7221	16 847	32 892	45 627	58 269	71 267	67 254	39 392	29 297
Lip, oral cavity and pharynx	C00-C14	1	7	14	2	36	39	58	71	123	261	543	1125	1157	1040	1060	1054	494	332
Esophagus	C15	0	2	0	0	0	0	0	22	61	304	717	1779	2364	2846	2604	2304	1196	619
Stomach	C16	4	0	0	6	46	66	168	435	1060	1708	4174	7786	10 330	12 802	14 933	13 373	7552	5659
Colon	C18	0	0	0	6	1	62	115	311	456	658	1786	3257	4635	5947	6828	6253	3979	2832
Rectum	C19-C20	0	0	0	5	4	20	120	171	406	734	1437	2830	3320	3508	3825	3184	1640	1140
Colon and rectum	C18-C20	0	0	0	11	5	82	235	482	862	1392	3223	6087	7955	9455	10 653	9437	5619	3972
Liver	C22	15	0	0	0	6	22	56	160	271	501	1523	2795	4111	4824	5840	4716	2448	1441
Gallbladder etc.	C23-C24	0	0	0	0	11	1	0	41	24	77	282	481	877	1241	1541	1908	1481	1272
Pancreas	C25	0	0	1	0	0	10	7	59	114	181	698	1216	1625	2214	2301	2049	1503	1130
Larynx	C32	0	0	0	0	0	0	0	12	23	28	160	454	723	690	550	721	343	199
Trachea, bronchus and lung	C33-C34	0	0	5	0	0	46	71	205	388	802	1889	4084	6049	7396	11 080	12 646	7755	5848
Melanoma of skin etc.	C43-C44	0	0	1	6	8	16	28	83	103	75	169	330	338	737	866	701	602	735
Prostate	C61	0	0	0	0	0	0	8	0	7	66	487	1844	4333	7797	10 615	9458	4869	3513
Bladder	C67	5	0	0	0	0	10	46	49	188	254	402	1051	1286	1506	2280	2461	1687	1394
Kidney, renal pelvis, ureter etc.	C64-C66 C68	16	23	0	0	1	23	29	85	262	306	649	1149	984	1565	1903	1462	765	536
Brain and nervous system	C70-C72	31	44	89	48	129	63	85	59	114	100	126	194	269	293	285	294	178	95
Thyroid	C73	0	0	0	18	36	58	81	105	65	123	215	361	247	245	221	217	106	28
Malignant lymphoma	C81-85 C96	9	43	22	77	48	69	141	228	264	381	597	674	1046	1302	1604	1521	892	749
Multiple myeloma	C88 C90	0	0	0	0	3	0	2	5	5	44	75	160	239	270	478	421	297	243
All leukaemias	C91-C95	162	84	48	64	112	82	156	149	117	164	275	365	439	671	777	750	478	307

Table 3. Age-specific incidence rate per 100 000 population in Japan according to sex and primary site, 2005

Primary sites	ICD-10th	Age group (years)																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
Male																			
All sites (incl. CIS)	C00-C96, D00-D09	14.4	8.3	8.6	9.6	18.5	21.8	32.3	59.8	114.1	195.0	401.9	670.4	1135.1	1701.3	2414.8	3061.1	3291.8	3665.7
All sites	C00-C96	14.4	8.1	8.6	9.5	18.5	21.3	32.0	57.7	108.8	186.7	384.4	647.8	1098.2	1643.7	2344.5	2980.7	3221.9	3612.9
Lip, oral cavity and pharynx	C00-C14	0.0	0.2	0.5	0.1	1.0	0.9	1.2	1.6	3.0	6.7	12.4	22.2	27.8	29.3	34.9	46.7	40.4	40.9
Esophagus	C15	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	1.5	7.9	16.4	35.0	56.9	80.3	85.7	102.1	97.8	76.3
Stomach	C16	0.1	0.0	0.0	0.2	1.2	1.6	3.4	9.9	26.1	44.2	95.2	153.3	248.6	361.1	491.3	592.7	617.7	697.9
Colon	C18	0.0	0.0	0.0	0.2	0.0	1.5	2.3	7.1	11.2	17.0	40.7	64.1	111.6	167.8	224.6	277.1	325.4	349.2
Rectum	C19-C20	0.0	0.0	0.0	0.1	0.1	0.5	2.4	3.9	10.0	19.0	32.8	55.7	79.9	99.0	125.8	141.1	134.1	140.6
Colon and rectum	C18-C20	0.0	0.0	0.0	0.3	0.1	2.0	4.8	10.9	21.2	36.0	73.5	119.9	191.5	266.7	350.5	418.2	459.6	489.8
Liver	C22	0.5	0.0	0.0	0.0	0.2	0.5	1.1	3.6	6.7	13.0	34.7	55.0	99.0	136.1	192.1	209.0	200.2	177.7
Gallbladder etc.	C23-C24	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.9	0.6	2.0	6.4	9.5	21.1	35.0	50.7	84.6	121.1	156.9
Pancreas	C25	0.0	0.0	0.0	0.0	0.0	0.2	0.1	1.3	2.8	4.7	15.9	23.9	39.1	62.5	75.7	90.8	122.9	139.4
Larynx	C32	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.7	3.7	8.9	17.4	19.5	18.1	32.0	28.1	24.5
Trachea, bronchus and lung	C33-C34	0.0	0.0	0.2	0.0	0.0	1.1	1.4	4.7	9.5	20.7	43.1	80.4	145.6	208.6	364.5	560.5	634.3	721.2
Melanoma of skin etc.	C43-C44	0.0	0.0	0.0	0.2	0.2	0.4	0.6	1.9	2.5	1.9	3.9	6.5	8.1	20.8	28.5	31.1	49.2	90.6
Prostate	C61	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.7	11.1	36.3	104.3	219.9	349.2	419.2	398.2	433.2
Bladder	C67	0.2	0.0	0.0	0.0	0.0	0.2	0.9	1.1	4.6	6.6	9.2	20.7	31.0	42.5	75.0	109.1	138.0	171.9
Kidney, renal pelvis, ureter etc.	C64-C66, C68	0.6	0.8	0.0	0.0	0.0	0.5	0.6	1.9	6.4	7.9	14.8	22.6	23.7	44.1	62.6	64.8	62.6	66.1
Brain and nervous system	C70-C72	1.1	1.4	2.9	1.4	3.4	1.5	1.7	1.3	2.8	2.6	2.9	3.8	6.5	8.3	9.4	13.0	14.6	11.7
Thyroid	C73	0.0	0.0	0.0	0.5	1.0	1.4	1.6	2.4	1.6	3.2	4.9	7.1	5.9	6.9	7.3	9.6	8.7	3.5
Malignant lymphoma	C81-85, C96	0.3	1.4	0.7	2.3	1.3	1.6	2.9	5.2	6.5	9.9	13.6	13.3	25.2	36.7	52.8	67.4	73.0	92.4
Multiple myeloma	C88, C90	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	1.1	1.7	3.2	5.8	7.6	15.7	18.7	24.3	30.0
All leukaemias	C91-C95	5.7	2.8	1.6	1.9	3.0	2.0	3.2	3.4	2.9	4.2	6.3	7.2	10.6	18.9	25.6	33.2	39.1	37.9




Figure 1. Trends of age-standardized cancer incidence rates for five major sites and specific sites for each sex (standard population: world population).




Figure 2. Trends of age-standardized cancer incidence rates for five major sites and specific sites for each sex (standard population: 1985 Japanese model population).

on the website (only available in Japanese, <http://ganjoho.jp/professional/statistics/monita.html>).

Acknowledgements

The survey on cancer incidence in Japan was conducted with contributions from the 30 registries: Hokkaido, Aomori, Iwate, Miyagi, Yamagata, Ibaraki, Tochigi, Gunma, Chiba, Kanagawa, Niigata, Toyama, Ishikawa, Fukui, Gifu, Aichi, Shiga, Kyoto, Tottori, Okayama, Hiroshima, Yamaguchi, Tokushima, Kagawa, Ehime, Kochi, Nagasaki, Kumamoto, Kagoshima and Okinawa.

Funding

The study was supported by the 3rd-term Comprehensive Ten-year Strategy for Cancer Control.

Conflict of interest statement

None declared.

References

1. Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 population-based cancer registries. *Jpn J Clin Oncol.* 2006;36:668–75.

2. Marugame T, Matsuda T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. *Jpn J Clin Oncol* 2007;37:884–91.
3. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. *Jpn J Clin Oncol* 2008;38:641–8.
4. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. *Jpn J Clin Oncol* 2009;39:850–8.
5. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2004: based on data from 14 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol* 2010; July 20 (Epub ahead of print).
6. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1988: estimates based on data from ten population-based Cancer Registries. *Jpn J Clin Oncol* 1994;24:299–304.
7. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence in Japan 1985–89: re-estimation based on data from eight population-based cancer registries. *Jpn J Clin Oncol* 1998;28: 54–67.
8. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence in Japan. In: Tajima K, Kuroishi T, Oshima A, editors. *Cancer Mortality and Morbidity Statistics—Japan and the World*. Tokyo: Japanese Scientific Societies Press 2004;95–130.

Original Article

Population-based Survival of Cancer Patients Diagnosed Between 1993 and 1999 in Japan: A Chronological and International Comparative Study

Tomohiro Matsuda^{1,*}, Wakiko Ajiki¹, Tomomi Marugame¹, Akiko Ioka², Hideaki Tsukuma² and Tomotaka Sobue¹,
Research Group of Population-Based Cancer Registries of Japan

¹Population-Based Cancer Registry Section, Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Chuo-ku, Tokyo and ²Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

*For reprints and all correspondence: Tomohiro Matsuda, Population-Based Cancer Registry Section, Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: tomatsud@ncc.go.jp

Received June 6, 2010; accepted August 6, 2010

Objective: The purpose of the present study was to collect data from population-based cancer registries and to calculate relative 5-year survival of cancer patients in Japan. We also sought to determine time trends and to compare the results with international studies.

Methods: We asked 11 population-based cancer registries to submit individual data for patients diagnosed from 1993 to 1999, together with data on outcome after 5 years. Although all these registries submitted data (491 772 cases), only six met the required standards for the quality of registration data and follow-up investigation. The relative 5-year survival calculated by pooling data from 151 061 cases from six registries was taken as the survival for cancer patients in Japan.

Results: Relative 5-year survival (1997–99) was 54.3% for all cancers (males: 50.0%, females: 59.8%). Survival figures for all sites changed slightly over the 7-year period, from 53.2% for the first 4 years of the study (1993–96) to 54.3% for the last 3 years (1997–99), however, a major improvement was observed in several primary sites. Some overall survival was lower in Japan than in the USA, but similar to that in European countries. Specifically, survival for uterine cancer, prostate cancer, testis cancer, lymphoma and leukemia was much lower in Japan than in other countries. However, survival was better in Japan mainly for cancers of the esophagus, stomach, colon, liver and gallbladder.

Conclusion: The study suggests an improvement in cancer survival in several primary sites in Japan, which is consistent with the development of treatments and early detection.

Key words: epidemiology/public health – prognostic factors – epidemiol-prevention

INTRODUCTION

Cancer survival, as assessed based on population-based cancer registries, is a valuable medical indicator to evaluate the progress of cancer control in a country or region. Precise population-based cancer survival is a comprehensive, practical and timely index for cancer control in a country. Use of

relative 5-year survival statistics is useful to evaluate therapeutic effect in cancer incidence/mortality trends in real time. Cancer survival has also been shown to be powerful when comparing survival between sex, age groups and socioeconomic groups or between geographic areas where incidence or death due to other causes may differ.

However, this information is not often available because of legislative, financial and technical difficulties in following-up patients, even in population-based cancer registries in developed nations.

Clinical research groups frequently publish hospital-based survival rates for cancer patients at specific medical facilities (1–3); however, these data do not provide useful information to political planners because of inevitable recruitment bias. Population-based survival is a thus prerequisite for designing public health projects and evaluating the efficacy of cancer prevention, screening and treatment.

In 1998, we proposed standard methods which required checking of vital status of patients by inquiring to the resident registration 5 years after diagnosis (4). We reported relative 5-year survival based on these methods for stomach, lung and breast cancer diagnosed from 1985 to 1989, using data from cancer registries of Yamagata, Fukui and Osaka Prefectures (5), which had collected data satisfying the methodological criteria. In 2001, we collected, from 12 registries belonging to the study group, individual data from all cancer patients (for all sites) diagnosed in 1993 for whom outcome information after 5 years was available. From this data we attempted to produce a nationwide relative 5-year survival according to standard methods (6). This nationwide survival, however, could not be completed because there were differences in the quality of registration and assessment methods of outcome among the 12 registries. A population-based survival was therefore not published in Japan until 2006 (7). This first population-based study reported that relative 5-year survival calculated by pooling 279 000 data from 7 registries was 49.2% for males and 59.4% for females.

The aims of the study were first to calculate the most recent relative 5-year survival of cancer patients in Japan, and second to observe changes in survival by comparing the data between two observation periods, 1993–96 and 1997–99, and by comparison with the results of international studies.

PATIENTS AND METHODS

Eleven among 15 registries (Miyagi, Yamagata, Niigata, Chiba, Kanagawa, Fukui, Aichi, Shiga, Osaka, Tottori, Okayama, Saga, Nagasaki, Kumamoto and Okinawa) submitted individual data (a total of 491 772 cases) to the survival study. These 15 registries were selected because they had relatively high-quality data tracing the 5-year outcome of patients diagnosed from 1993 to 1999. They had also participated in the Monitoring of Cancer Incidence in Japan (MCIJ) project for 2002 incident cases (8). We requested 11 population-based cancer registries to submit patient data for cancers at all sites, diagnosed from 1993 to 1999, including information on outcome after 5 years. We pooled cancer registry data that met standards of data quality in terms of both registration and outcome assessment.

QUALITY CRITERIA FOR AREA SELECTION

The quality criteria were based on the standards adopted in the above-mentioned MCIJ project: DCO% (death certificate only: proportion of patients for whom the death certificate provides the only notification to the registry) <25% or DCN% (death certificate notification: proportion of patients for whom the death certificate provides the first notification to the registry) <30%, and IM ratio (incidence to mortality ratio) less than 1.5 (8). Among the 11 registries, six (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki) met the required standards for the quality of registration and outcome assessment. According to the data provided by these registries, we calculated survival rates and considered them to be a nationwide index.

As far as the quality of outcome assessment was concerned, we set two criteria relating to follow-up methods. For registries checking survival of patients by referring to resident registries (active follow-up; Yamagata, Fukui and Osaka), we specified that the proportion of outcome-unknown cases 5 years after diagnosis should be <5%. For registries having no confirmation of survival 5 years after diagnosis (passive follow-up; Miyagi, Niigata and Nagasaki), we specified that information on personal identification including names would be computerized in order to collate the registered patients with death information with high accuracy. Registries that met these criteria were therefore guaranteed to have sufficiently accurate information about death.

SURVIVAL CALCULATION

Referring to other studies, since 1996 the research group has set standardized methods of calculating survival in Japan through the collaborative study of population-based cancer registries. The method of calculating survival is mainly based on the EURO CARE study (9). In concrete terms, we excluded DCO cases, cancers *in situ* and mucosal cancers of the large bowel from the analysis. In the case of multiple cancers, only the first-diagnosed tumor was analyzed.

This study calculated the survival for cancers including followed-back cases from DCN (Subjects 1) and excluding these cases (Subjects 2). The former method was that used in the EURO CARE study, and is suitable for international comparison of survival based on population-based cancer registries. The latter should instead be utilized for domestic comparison of survival in Japan where some registries do not conduct follow-back inquiries to medical institutions for DCN cases, according to death certificate information.

Survival for Subjects 2 is generally better than that for Subjects 1 because the latter include cases regarded as incident according to death information. Given the high proportion of incident cases not reported by medical facilities but registered on the basis of death certificates, the survival calculated for Subjects 1 may be underestimated. In contrast, it is also possible for survival to be overestimated in Subjects 2. In Japan, each population-based registry decides

whether to apply active follow-up; consequently, the survival of Subjects 2 would be better than that of Subjects 1. In this study, we will regard the survival calculated for Subjects 2 as that of cancer patients in Japan.

Cumulative 5-year survivals were calculated starting from the date of diagnosis. Expected survivals were calculated using the cohort survival table based on life tables of the Japanese population and then using the survival probability in the general population similar to the patients in sex, birth year and age. The former were divided by the latter to obtain relative 5-year survivals.

If vital status was unknown at 5 years after diagnosis, cases were dealt with as alive at the last contact date (5). However, for the three registries that had not checked the survival of patients by referring to the resident registry, we regarded all cases whose death was not confirmed as being alive until 5 years, and survival was calculated on this basis.

RESULTS

SURVIVAL DATA QUALITY

Table 1 shows the number of incident cases, validity indices of registration, and the number of study subjects for survival

analysis, for each registry in the two studies. In 1997–99 there were 221 080 incident cases, and the following cases were excluded from the survival analysis: DCO (36 939 cases, 16.7% of the total), subsequent primary tumors (17 814 cases, 8.1% of the total), non-malignant tumors (565 cases, 0.3% of the total), and *in situ* cancers (3 264 cases, 1.5% of the total). In addition, after excluding patients with unknown age at diagnosis and those over 100 years old, we considered the rest (164 738 cases, 74.5% of the total) as Subjects 1. Moreover, for DCN cases, additional cancer reports were requested in Yamagata, Fukui and Osaka Prefectures, and the registry records of cases originating from death information were distinguished in Miyagi Prefecture. The number of cases in which we traced the death information to incidence was 13 677, 8.3% of the total. The number of final analysis subjects (Subjects 2) excluding these cases was 151 061, corresponding to 68.3% of the total.

Table 2 shows the vital status at 5 years from diagnosis. In the Miyagi, Yamagata and Niigata Cancer Registries, in which the vital status of patients was checked after 5 years by referring to resident registries, the proportion of cases with unknown vital status was 2.0% among these three registries. Survival rate varied from 38.0 to 45.8%.

Table 1. Number of incident cases, validity indices of registration and number of study subjects for survival calculations, according to registry—cases diagnosed in 1993–96 (the previous study) and in 1997–99

Observation period	Registry	n	DCO		Subsequent primary		Non-malignant tumors		CIS		Subjects 1		Follow-back cases		Subjects 2	
			n	% ^a	n	% ^a	n	% ^a	n	% ^a	n	% ^a	n	% ^b	n	% ^a
1993–96	Miyagi	37 194	5709	15.3	4359	11.7	127	0.3	919	2.5	26 832	72.1	183	0.7	26 649	71.6
	Yamagata	24 416	2546	10.4	1211	5.0	0	0.0	285	1.2	20 406	83.6	2531	12.4	17 875	73.2
	Niigata	44 818	10 843	24.2	1621	3.6	5	0.0	495	1.1	31 867	71.1	—	—	31 867	71.1
	Fukui	13 886	575	4.1	797	5.7	3	0.0	153	1.1	12 395	89.3	1586	12.8	10 809	77.8
	Osaka	120 040	23 386	19.5	7488	6.2	360	0.3	1507	1.3	88 551	73.8	13 411	15.1	75 140	62.6
	Nagasaki	30 338	2790	9.2	2663	8.8	0	0.0	601	2.0	24 576	81.0	—	—	24 576	81.0
	Total	270 692	45 849	16.9	18 139	6.7	495	0.2	3960	1.5	204 627	75.6	17 711	8.7	186 916	69.1
1997–99	Miyagi	32 439	4232	13.0	4015	12.4	181	0.6	767	2.4	23 741	73.2	844	3.6	22 897	70.6
	Yamagata	19 248	1949	10.1	1202	6.2	1	0.0	195	1.0	15 953	82.9	1709	10.7	14 244	74.0
	Niigata	35 908	8737	24.3	1958	5.5	18	0.1	387	1.1	24 824	69.1	—	—	24 824	69.1
	Fukui	11 559	562	4.9	922	8.0	14	0.1	132	1.1	9974	86.3	1016	10.2	8958	77.5
	Osaka	97 641	19 268	19.7	7050	7.2	351	0.4	1223	1.3	71 093	72.8	10 108	14.2	60 985	62.5
	Nagasaki	24 285	2191	9.0	2667	11.0	0	0.0	560	2.3	19 153	78.9	—	—	19 153	78.9
	Total	221 080	36 939	16.7	17 814	8.1	565	0.3	3264	1.5	164 738	74.5	13 677	8.3	151 061	68.3
Total	491 772	82 788	16.8	35 953	7.3	1060	0.2	7224	1.5	369 365	75.1	31 388	8.5	337 977	68.7	

DCO, Death certificate only cases; Follow-back cases: cases notified by death certificates require follow-back to obtain their clinical information.

Subjects 1: including followed-back cases from DCN; Subject 2: excluding followed-back cases.

^aProportion of total cases.

^bProportion of Subject 1 cases.

Table 2. Vital status at 5 years from diagnosis

Registry	Subjects 1	Dead		Alive		Unknown		Survival proportion (excl. unknown cases), %
		<i>n</i>	% ^a	<i>n</i>	% ^a	<i>n</i>	% ^a	
1993–96								
Active follow-up								
Yamagata	20 406	11 041	54.1	9219	45.2	146	0.7	45.5
Fukui	12 395	6905	55.7	5111	41.2	379	3.1	42.5
Osaka	88 551	54 229	61.2	32 447	36.6	1875	2.1	37.4
Total	121 352	72 175	59.5	46 777	38.5	2400	2.0	43.9
Passive follow-up								
Niigata	31 867	15 183	47.6	16 684	52.4	—	—	—
Miyagi	26 832	12 811	47.7	14 021	52.3	—	—	—
Nagasaki	24 576	13 180	53.6	11 396	46.4	—	—	—
Total	204 627	113 349	55.4	88 878	43.4	—	—	—
1997–99								
Active follow-up								
Yamagata	15 953	8563	53.7	7231	45.3	159	1.0	45.8
Fukui	9974	5377	53.9	4238	42.5	359	3.6	44.1
Osaka	71 093	43 135	60.7	26 399	37.1	1559	2.2	38.0
Total	97 020	57 075	58.8	37 868	39.0	2077	2.1	44.8
Passive follow-up								
Niigata	24 824	11 541	46.5	13 283	53.5	—	—	—
Miyagi	23 741	11 256	47.4	12 485	52.6	—	—	—
Nagasaki	19 153	9885	51.6	9268	48.4	—	—	—
Total	164 738	89 757	54.5	72 904	44.3	—	—	—
Total	369 365	203 106	55.0	161 782	43.8	—	—	—

^aProportion of total cases.

SURVIVAL BY AGE AND SEX

Table 3 shows 5-year relative survival rate and standard error according to the primary site and sex, excluding the follow-back cases (i.e. in Subjects 2). The 5-year relative survival was 53.2% for all cancers diagnosed in 1993–96 (M: 48.9%, F: 59.0%), while that for 1997–99 was 54.3% (M: 50.0%, F: 59.8%).

When all sites were considered together, females had a higher survival than males (M: 50.0%, F: 59.8%). This tendency was evident for lip, oral cavity and pharynx (M: 48.3% vs. F: 63.0%) and lung cancer (M: 22.4% vs. F: 33.5%). In contrast, females had a lower survival than males in for cancers of the larynx (M: 77.0% vs. F: 64.4%) and bladder (M: 78.6% vs. F: 69.8%).

The relative 5-year survivals for all sites decreased markedly in the elderly. In males, this difference was pronounced for cancers of the lip, oral cavity and pharynx, bladder and thyroid, as well as in malignant lymphoma and all leukemias. For women, there was a marked age-related decrease in survival for cancers of the lip, oral cavity and pharynx

and uterus (cervix and corpus), as well as malignant lymphoma, multiple myeloma and all leukemias (Fig. 1).

SURVIVAL AND TIME TRENDS FOR SURVIVAL BY PRIMARY SITE

Survival probabilities for cancers of the cervix, prostate, larynx, bladder, corpus uteri, female breast, testis and thyroid ranged from 71.5 to 92.4%; those for ovary, mouth, oral cavity and pharynx, stomach, rectum and anus, and colon ranged from 52.0 to 68.9%; those for pancreas, gall-bladder, liver, lung, multiple myeloma, esophagus, all leukemias and malignant lymphoma ranged from 6.7 to 49.9% (Table 3).

Survival figures for all sites improved significantly over the 7-year period, increasing from 53.2% for the first observation period (1993–96) to 54.3% in the second (1997–99) (Table 3). Proportion of localized tumor at diagnosis increased; 43.0–52.0% for prostate, 5.4–10.1% for multiple myeloma, 25.0–28.6% for lung, 26.7–29.3 for malignant lymphoma, 43.3–45.5% for lip, oral cavity and pharynx,

Table 3. Relative 5-year survival by sex for selected sites of cancer diagnosed in 1993–96 and in 1997–99 (Subjects 2)

Primary sites	Male			Female			Total		
	n	Relative survival rate		n	Relative survival rate		n	Relative survival rate	
		%	SE		%	SE		%	SE
1993–96									
All sites (C00–C96)	106 022	48.9	0.2	77 473	59.0	0.2	183 495	53.2	0.1
Lip, oral cavity and pharynx (C00–C14)	2535	48.6	1.1	1022	64.7	1.7	3557	53.2	0.9
Esophagus (C15)	4401	25.7	0.7	843	33.1	1.7	5244	26.9	0.7
Stomach (C16)	29 318	62.1	0.3	14 817	60.4	0.5	44 135	61.6	0.3
Colon (C18)	10 542	71.3	0.6	8609	66.1	0.6	19 151	68.9	0.4
Rectum and anus (C19–C21)	7089	65.0	0.7	4316	63.9	0.8	11 405	64.6	0.5
Liver (C22)	9958	21.0	0.4	3619	21.8	0.7	13 577	21.2	0.4
Gallbladder etc. (C23–C24)	2475	19.0	0.9	2962	20.1	0.8	5437	19.6	0.6
Pancreas (C25)	2855	7.0	0.5	2205	5.9	0.5	5060	6.5	0.4
Larynx (C32)	1570	78.2	1.4	90	75.9	6.3	1660	78.1	1.4
Trachea, bronchus and lung (C33–C34)	15 124	20.8	0.4	5618	27.1	0.6	20 742	22.5	0.3
Female breast (C50)				14 094	84.4	0.4	14 094	84.4	0.4
Uterus (C53–C55)				5332	74.4	0.7	5332	74.4	0.7
Cervix uteri (C53)				3472	73.4	0.8	3472	73.4	0.8
Corpus uteri (C54)				1688	79.5	1.1	1688	79.5	1.1
Ovary (C56)				2116	49.4	1.1	2116	49.4	1.1
Prostate (C61)	4220	66.8	1.0				4220	66.8	1.0
Testis (C63)	505	89.6	1.6				505	89.6	1.6
Bladder (C67)	3481	80.0	1.0	1049	70.6	1.8	4530	77.8	0.9
Thyroid (C73)	541	86.3	2.1	2483	93.2	0.7	3024	92.0	0.7
Malignant lymphoma (C81–85, C96)	2349	46.3	1.1	1800	51.4	1.3	4149	48.5	0.9
Multiple myeloma (C88, C90)	508	29.3	2.2	446	30.9	2.3	954	30.0	1.6
All leukemias (C91–C95)	1686	31.7	1.2	1234	33.2	1.4	2920	32.3	0.9
1997–99									
All sites (C00–C96)	84 851	50.0	0.2↑**	62 860	59.8	0.2↑**	147 711	54.3	0.1↑**
Lip, oral cavity and pharynx (C00–C14)	1853	48.3	1.3	854	63.0	1.9	2707	52.9	1.1
Esophagus (C15)	3834	30.7	0.8↑**	643	37.3	2.0	4477	31.6	0.8↑**
Stomach (C16)	2190	62.6	0.4	10 485	61.2	0.5	32 375	62.1	0.3
Colon (C18)	8370	71.0	0.6	7106	66.4	0.7	15 476	68.9	0.5
Rectum and anus (C19–C21)	5797	65.7	0.8	3475	64.5	0.9	9272	65.2	0.6
Liver (C22)	7689	23.7	0.5↑**	3118	21.8	0.8	10 807	23.1	0.4↑**
Gallbladder etc. (C23–C24)	1884	21.8	1.1↑*	2430	18.9	0.8	4314	20.2	0.7
Pancreas (C25)	2386	6.2	0.5	1900	7.3	0.6	4286	6.7	0.4
Larynx (C32)	1130	77.0	1.7	78	64.4	6.6	1208	76.1	1.6
Trachea, bronchus and lung (C33–C34)	12 737	22.4	0.4↑**	4963	33.5	0.7↑**	17 700	25.6	0.4↑**
Female breast (C50)				12 334	85.5	0.4	12 334	85.5	0.4
Uterus (C53–C55)				3995	72.5	0.8	3995	72.5	0.8
Cervix uteri (C53)				2244	71.5	1.1	2244	71.5	1.1

Continued

Downloaded from jco.oxfordjournals.org at National Cancer Centre (JMILA) on October 7, 2010

Table 3. Continued

Primary sites	Male			Female			Total		
	n	Relative survival rate		n	Relative survival rate		n	Relative survival rate	
		%	SE		%	SE		%	SE
Corpus uteri (C54)				1571	76.8	1.2	1571	76.8	1.2
Ovary (C56)				1800	52.0	1.2	1800	52.0	1.2
Prostate (C61)	4508	75.5	1.0↑**				4508	75.5	1.0↑**
Testis (C63)	369	92.0	1.9				369	92.0	1.9
Bladder (C67)	2824	78.6	1.1	870	69.8	2.0	3694	76.5	1.0
Thyroid (C73)	437	87.6	2.3	1986	93.5	0.8	2423	92.4	0.7
Malignant lymphoma (C81–85, C96)	1949	46.6	1.3	1473	54.2	1.4	3422	49.9	0.9
Multiple myeloma (C88, C90)	422	31.5	2.5	403	28.1	2.4	825	29.8	1.7
All leukemias (C91–C95)	1242	32.2	1.4	986	33.8	1.6	2228	32.9	1.0

↑Improved significantly between the two observation periods ** $P < 0.01$, * $P < 0.05$.

31.6–33.5% for esophagus, 34.5–36.4% for ovary, 70.1–71.7% for liver and 55.6–57.2% for female breast. Accordingly survival also improved significantly for cancers of the prostate (by 8.7 points), esophagus (by 4.7 points), lung (by 3.1 points) and liver (by 1.9 points).

SURVIVAL AND TIME TRENDS FOR SURVIVAL BY EXTENT OF DISEASE

Table 4 shows observed and relative 5-year survival by extent of disease at diagnosis. Relative survival for all sites (C00–C96) was 85.2% for localized tumors, 43.7% for those with regional lymph node or direct invasion to the adjacent tissue/organ and 10.1% for those with distant metastasis. When all sites were considered together, improvement in survival was found only for localized tumors; survival rate increased from 84.6 to 85.2% ($P < 0.05$).

Among localized tumors, survival improvement between the two periods was observed for the esophagus, liver, lung and female breast; among tumors with regional lymph node or direct invasion to the adjacent tissue/organ, improvement was seen for the pancreas, lung, prostate and testis. No improvement was observed in distant metastatic tumor cases.

In contrast, survival deteriorated significantly between the two observation periods for localized bladder cancer, laryngeal cancer with regional lymph node or adjacent organ metastasis, and gallbladder cancer with distant metastasis.

COMPARISON WITH INTERNATIONAL DATA

Table 5 shows relative 5-year survivals in the current study, SEER study (10) and EURO CARE4 study (11). Compared with the American data (SEER study), overall all-age survival was lower in Japan (64.9–54.3%); however,

age-standardized survival in Japan was similar to that in European countries (53.3–51.9%). In particular, the survivals for Japanese patients with uterine cancer, prostate cancer, testicular cancer, lymphoma and leukemia were much lower than for their American counterparts. Survival in Japan was better than in Europe or the USA mainly for cancers of the digestive and hepatobiliary organs, such as the esophagus, stomach, colon, liver and gallbladder.

DISCUSSION

SURVIVAL IN JAPAN

On the basis of the data from six population-based cancer registries in Japan that met standards for data quality in terms of both registration and outcome assessment, we calculated the latest relative 5-year survival for major cancers.

Age differences were observed in survival when all sites were considered together and in some specific primary sites. Ioka et al. (12) found that advanced cervical cancers leading to poor survival are common in older people. Otherwise, this may be explained by histological differences or simply physical decline in older patients. Farley et al. (13) reported a similar decreasing survival with age in their study of uterine cancer. Studies of leukemia (14) and bladder cancer (15) also show similar effects of age.

Sex differences in survival for cancers at two primary sites, the larynx and lung, might be caused by biological differences between the two sexes and diagnostic circumstances. These differences could relate to smoking behavior in the two sexes, even for cancers of the same histology. Nordquist et al. (16) found differences in survival according to the smoking status of patients with adenocarcinoma of the lung. Another study showed that the survival of bladder




Figure 1. Relative 5-year survival for major sites of cancer by sex and age at diagnosis (1997-99, Subject 2).

cancer patients varies according to current smoking, age and gender, in addition to a latent promoter hypermethylation (17). Bladder cancer is often at a more advanced tumor stage at diagnosis in women than in men.

COMPARISON BETWEEN THE TWO PERIODS AND WITH THE RESULTS OF INTERNATIONAL STUDIES

Overall chronological improvement of survival in several primary sites was observed, confirming the findings of a